Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Effects of neoadjuvant intraperitoneal/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer
International Journal of Surgical Oncology, Volume 2012, Article 148420, Year 2012
Notification
URL copied to clipboard!
Description
Novel multidisciplinary treatment combined with neoadjuvant intraperitoneal-systemic chemotherapy protocol (NIPS) and peritonectomy was developed. Ninety-six patients were enrolled. Peritoneal wash cytology was performed before and after NIPS through a port system. Patients were treated with 60 mg/m 2 of oral S-1 for 21 days, followed by a 1-week rest. On days 1, 8, and 15, 30 mg/m 2 of Taxotere and 30 mg/m 2 of cisplatin with 500 mL of saline were introduced through the port. NIPS is done 2 cycles before surgery. Three weeks after NIPS, 82 patients were eligible to intend cytoreductive surgery (CRS) by gastrectomy + D2 dissection + periotnectomy to achieve complete cytoreduction. Sixty-eight patients showed positice cytology before NIPS, and the positive cytology results became negative in 47 (69) patients after NIPS. Complete pathologic response on PC after NIPS was experienced in 30 (36.8) patients. Stage migration was experienced in 12 patients (14.6). Complete cytoreduction was achieved in 58 patients (70.7). By the multivariate analysis, complete cytoreduction and pathologic response became a significantly good survival. However the high morbidity and mortality, stringent patient selection is important. The best indications of the therapy are patients with good pathologic response and PCI ≤ 6, which are supposed to be removed completely by peritonectomy. © 2012 Yutaka Yonemura et al.
Authors & Co-Authors
Yonemura, Yutaka
Japan, Kishiwada
Npo Organization to Support Peritoneal Surface Malignancy Treatment
Japan, Kusatsu
Omi Medical Center
Japan, Kishiwada
Kishiwada Tokushukai Hospital
Elnemr, Ayman
Japan, Kishiwada
Npo Organization to Support Peritoneal Surface Malignancy Treatment
Egypt, Tanta
Tanta University Hospitals
Endou, Yoshio
Japan, Kanazawa
Kanazawa University
Ishibashi, Haruaki
Japan, Kishiwada
Npo Organization to Support Peritoneal Surface Malignancy Treatment
Japan, Kishiwada
Kishiwada Tokushukai Hospital
Mizumoto, Akiyoshi
Japan, Kusatsu
Omi Medical Center
Miura, Masahiro
Japan, Yufu
Oita University Faculty of Medicine
Li, Yan
China, Wuhan
Wuhan University
Statistics
Citations: 82
Authors: 7
Affiliations: 7
Identifiers
Doi:
10.1155/2012/148420
ISSN:
20901402
Research Areas
Cancer
Health System And Policy